BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210526T110000
DTEND;TZID=America/New_York:20210526T120000
DTSTAMP:20260415T073003
CREATED:20210521T172351Z
LAST-MODIFIED:20210521T172351Z
UID:2164-1622026800-1622030400@www.mdtechcouncil.com
SUMMARY:NCI Technology Licensing Opportunity Webinar: Complete Tumor Regression in Colon Cancer & Leukemia with Novel Cytidine Compound
DESCRIPTION:\n\n\n\nThis webinar introduces a novel therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia\, producing complete regression in xenograph mouse models (with minimal effects on body weight). In this webinar\, you will learn how this novel compound has superior efficacy over several FDA approved cancer cytidine-based therapeutics (e.g.\, gemcitabine\, azacytidine and decitabine) and why this compound shows promise as a potentially superior therapeutic treatment for colon cancer and leukemia. Among some of the superior aspects of this novel compound are its ability to provide complete and durable tumor regression in study animals beyond post-implant day 150 and its evidence of oral activity\, which expands options for route of administration beyond the current FDA approved cytidine-based injectable therapeutics.\n\n\n\n\n
URL:https://www.mdtechcouncil.com/membership/events/calendar/nci-technology-licensing-opportunity-webinar-complete-tumor-regression-in-colon-cancer-leukemia-with-novel-cytidine-compound/
CATEGORIES:Life Science
END:VEVENT
END:VCALENDAR